American Journal of Cardiology
Volume 106, Issue 6 , Pages 757-763, 15 September 2010

Contribution of High Plasma Triglycerides and Low High-Density Lipoprotein Cholesterol to Residual Risk of Coronary Heart Disease After Establishment of Low-Density Lipoprotein Cholesterol Control

  • Vincent J. Carey, PhD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: (617) 525-2265; fax: (617) 731-1541
  • ,
  • Louise Bishop, BS

      Affiliations

    • Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts
  • ,
  • Nancy Laranjo, BA

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Benjamin J. Harshfield, BA

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Carolyn Kwiat, BA

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Frank M. Sacks, MD

      Affiliations

    • Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
    • Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts

Received 26 February 2010; accepted 6 May 2010. published online 02 August 2010.

To determine the relative contributions of triglycerides (TGs) and high-density lipoprotein (HDL) cholesterol in the residual risk of coronary heart disease (CHD) after the reduction of low-density lipoprotein (LDL) cholesterol to guideline-recommended levels, we conducted a hospital-based, case-control study with optimal matching in the strata of LDL cholesterol, gender, ethnicity, and age. The 170 cases and 175 controls were patients at Brigham and Women's Hospital (Boston, Massachusetts) from 2005 to 2008 who had an LDL cholesterol level <130 mg/dl. The cases had incident CHD, and the controls had diagnoses unrelated to CHD. The 170 cases and 175 controls had a mean LDL cholesterol level of 73 and 87 mg/dl, respectively. The association between TG and HDL cholesterol levels and CHD risk was assessed using conditional and unconditional logistic regression analysis. The models investigated accommodated the possibility of an interaction between lipid factors. The odds of CHD increased by approximately 20% per 23-mg/dl increase in TGs and decreased by approximately 40% per 7.5-mg/dl decrease in HDL cholesterol. High TGs and low HDL cholesterol interacted synergistically to increase the odds ratio to 10 for the combined greatest TG (≥190 mg/dl) and lowest HDL cholesterol quintiles (<30 mg/dl). High TG levels were more strongly associated with CHD when the HDL cholesterol was low than average or high; and low HDL cholesterol levels were more strongly associated with CHD when the TGs were high. TGs and HDL cholesterol were associated with CHD in patients with a LDL cholesterol level of ≤70 mg/dl, with a risk similar to, or greater than, those in the total group. In conclusion, high TG and low HDL cholesterol levels contribute strongly and synergistically to CHD when LDL cholesterol is well controlled. Thus, high TGs might have greater importance in patients with optimal rather than greater LDL cholesterol concentrations.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Supported by the Residual Risk Reduction Initiative (R3I) Foundation (available at www.r3i.org). This Foundation has been a recipient of financial sponsorship solely from Solvay Pharmaceuticals (Abbott, Abbott Park, Illinois), although additional sponsors are actively sought. We have developed the methods and content for this research project and report with complete academic independence from the corporate sponsor of the Foundation.

PII: S0002-9149(10)01033-7

doi:10.1016/j.amjcard.2010.05.002

American Journal of Cardiology
Volume 106, Issue 6 , Pages 757-763, 15 September 2010